About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT00346086

DNA Vaccine for Ragweed Allergic Adults

Various chemical modifications of allergens have been attempted to enhance efficacy, improve safety, and foster compliance with IT. These approaches have been unsuccessful - in that the allergenicity ...

Lead sponsor: Johns Hopkins University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Johns Hopkins University

Evaluation of efficacy and safety of allergen-CpG oligonucleotide immunostimulatory conjugate in treatment of ragweed-induced seasonal allergic rhinitis. Study incorporates clinical outcomes (symptom diaries, medication diaries, visual analog scores, quality of life questionnaires), safety measurements, immunologic assays (antibody measurements, T-cell assays, cytokine assays, nasal provocation).

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adult men and women 18 to 60 years of age;
•Who provide informed consent;
•Have a history of fall, seasonal, allergic rhinitis consistent with ragweed allergy;
•Exhibit a positive skin test to licensed , standardized, ragweed extract and a positive acute response to ragweed nasal challenge;
•Are in general good health; and are available for the duration of the study.

Exclusion Criteria

•Individuals with medical conditions or taking medications that might interfere with interpretation of the study results will be excluded.
•Those with a history of severe symptoms of allergic rhinitis during the spring and summer grass pollen season will be excluded.

Related studies

Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis

NCT04815668 · Seasonal Allergic Rhinitis

RECRUITINGPhase 2/3

Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis

NCT06846385 · Seasonal Allergic Rhinitis

Active Not RecruitingPhase 2

A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis

NCT06837233 · Seasonal Allergic Rhinitis

COMPLETEDPhase 2

Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult

NCT06046391 · Seasonal Allergic Rhinitis

COMPLETEDPhase 1

A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients

NCT03570957 · Seasonal Allergic Rhinitis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 13, 2018Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment25

Start dateMay 2001

Last updatedDec 13, 2018

Condition

Seasonal Allergic Rhinitis

Locations shown

Johns Hopkins University School of Medicine

Baltimore, Maryland

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 13, 2018Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions